Guggenheim Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $16
Portfolio Pulse from Benzinga Newsdesk
Guggenheim has initiated coverage on Tenax Therapeutics with a Buy rating and set a price target of $16.
October 14, 2024 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim has initiated coverage on Tenax Therapeutics with a Buy rating and a price target of $16, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $16 by Guggenheim suggests a positive sentiment towards Tenax Therapeutics. This is likely to boost investor confidence and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100